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Pachyonychia congenita (PC) is one of a number of epithelial
fragility disorders that has been linked to mutations in keratin
genes over the last decade (Smith, 2003). Keratins belong to
the intermediate filament family of proteins that provide a
structural cytoskeleton within all epithelial cells. When
compromised by keratin mutations, epithelial cells become
fragile and less resilient to mild physical trauma. Clinically,
this presents as a variety of phenotypes depending on the
keratin affected, ranging from blistering in epidermolysis
bullosa simplex (EBS) to hypertrophic nail dystrophy in PC.
Nineteen keratin genes have now been identified in human
epithelial fragility disorders and some keratin mutations are
now emerging as predisposing factors in more common
multifactorial diseases (Smith, 2003). Four keratin genes are
known to be responsible for the main types of PC and
variants thereof, allowing diagnosis at the molecular level to
confirm the clinical diagnosis. This allows genetic counseling
with knowledge of the precise genetic lesion, with the option
of prenatal testing in severe cases. Molecular diagnosis is
also very useful to determine the type of PC in cases of
young children where some of the phenotypic character-
istics do not develop until later in life.
PC encompasses a variety of inherited ectodermal
dysplasias whose main clinical characteristic is hyper-
trophic nail dystrophy. Typically, thickening of the nails
begins within the first few months of life, as illustrated in
Fig 1. It is the constellation of other ectodermal struc-
tures affected which allows classification of PC into two
main types: PC-1 (Jadassohn-Lewandowsky type, OMIM
167200); and PC-2 (Jackson-Lawler type, OMIM 167210). In
PC-1, hypertrophic nail dystrophy is accompanied by focal
palmoplantar keratoderma, which is often quite severe and
debilitating, and oral leukokeratosis. The presence of
multiple pilosebaceous cysts in PC-2 is the predominant
feature distinguishing it from PC-1. However, these cysts
are not normally present until puberty when the sebaceous
glands become active, thus making the diagnosis of PC-1
versus PC-2 difficult in young children. Also, in PC-2 there
may be other ectodermal defects including: oral leuko-
keratosis (less common than in PC-1), mild focal palmo-
plantar keratoderma; pili torti; and natal teeth. The causative
keratin genes are specifically expressed in the nail bed,
palmoplantar epidermis, epidermal appendages and other
epithelia affected in each type of PC. Mutations in keratins
K6a and K16 result in PC-1 (Bowden et al, 1995; McLean
et al, 1995); whereas genetic defects in K6b and K17 lead
to PC-2 (McLean et al, 1995; Smith et al, 1998). The
expression patterns of these proteins and associated
phenotypes are summarized in Table 1.
In this issue, Xiao et al describe an unusual PC-2 case
where the proband did not show any phenotype until 12
years of age when she developed thickened toenails. Later,
at about 20 years of age her fingernails also became
thickened. Pilosebaceous cysts developed at puberty, as is
usual in PC-2. Other family members showed similar late-
onset nail abnormalities. This type of PC could be classified
as pachyonychia congenita tarda, a previously described
variant of PC (Paller et al, 1991; Hannaford and Stapleton,
2000). In these individuals hypertrophic nail changes do not
develop until the second or third decade of life. Xiao and
colleagues found K17 mutation N109D in this kindred, the
first genetic defect in a case of late-onset PC-2. The
mutation differs from those reported previously in K17 as it
is located in the second half of the 1A domain. With the
exception of one mutation in K6b, all reported PC-2
mutations occur within the helix initiation motif at the start
of the 1A domain of K17 (www.interfil.org). However, as more
PC families are analyzed, it is likely that mutations will be
found throughout the K17 molecule. The majority of keratin
mutations in epithelial fragility disorders are in the highly
conserved boundary domains at either end of the
a-helical rod domain (Fig 2). By in vitro experiments, these
regions have been demonstrated to be important in keratin
filament assembly, and mutations in these regions shown to
be highly disruptive to the integrity of keratin filament
networks. From studies in the keratin disorder EBS, where
Figure1
A baby with PC-1 at about 1 yr of age, showing early onset of the
marked hypertrophic nail dystrophy that is characteristic of the
disorder. This infant carries a mutation in the K6a gene. (Photograph
kindly provided by Dr Frances Lawlor and Professor John McGrath, St
John’s Institute of Dermatology, London).
Copyright r 2004 by The Society for Investigative Dermatology, Inc.
x
a large number of mutations have been identified in K5 and
K14, a good correlation can be drawn between the position
of the mutation and the clinical phenotype. In general,
mutations in the helix boundary motifs result in a more severe
phenotype than those in either the non-helical domains or in
internal regions of the a helical rod domain (Fig 2).
Here the authors (Xiao et al, p 892) speculate that the later
onset of PC-2 in this kindred could be explained by the
position of the mutation. The mutation, in the second half of
the 1A domain of K17, is in one of the less critical domains
which might delay the onset of the clinical phenotype. There
is one other report of a mutation in late-onset PC, in this case
the phenotype resembled PC-1 and was due to a mutation in
K16 (Connors et al, 2001). The mutation was again found in a
functionally less important region of the keratin molecule, the
central portion of the 2B domain, where mutations in the
analogous region of K5 and K14 result in the milder forms of
EBS. Thus, a trend is emerging where the types of mutations
associated with milder, site-restricted forms of EBS appear
to give rise to late-onset phenotypes in PC.
As more mutations are identified in PC kindreds including
those with unusual variants of PC as described by Xiao et al,
better genotype/phenotype correlations may be possible.
However, from the studies published so far it appears that
any genotype/phenotype association for PC could be more
complicated than in EBS. Steatocystoma multiplex (SM;
OMIM 184500) is another variant of PC-2 caused by mutations
in K17. Patients present clinically with widespread pilosebac-
eous cysts as seen in PC-2, but there is little or no nail
involvement. From the genotype/phenotype pattern seen in
EBS, one might have predicted that mutations causing SM
would be within the rod domain or variable regions and not in
the helix boundary motifs. However, the only mutations
reported in SM to date are in the helix initiation motif of K17,
with some mutations actually occurring at the same codon as
those that produce PC-2 (www.interfil.org). In another unusual
case of PC-2, sebaceous cysts developed at a very early age
(Feng et al, 2003) and here the mutation in K17 was found in
the same codon (N92) that can also result PC-2 and SM.
Clearly, there must be other factors in combination with the
mutation that determine the differing phenotypes in these
cases. These could be environmental/lifestyle factors, poly-
morphisms in other keratins, or in the case of early-onset
pilosebaceous cysts, hormonal variability could well be
involved. Another level of complexity is the fact that some
patients with clinical features resembling PC have recently
been shown to carry connexin mutations analogous to those
seen in Clouston syndrome (van Steensel et al, 2003). Thus,
there are still a number of unanswered questions in this area of
genodermatology.
In conclusion, another molecular piece of the pachy-
onychia puzzle has been ‘‘nailed’’. This and similar studies
help dermatologists and geneticists make informed diag-
noses and allow better prognostic predictions and genetic
testing for patients. Ultimately, a fuller understanding of
the pathogenetic mechanisms underlying these inherited
disorders may help biologists develop novel therapeutic
approaches to treat these incurable diseases.
DOI: 10.1111/j.0022-202X.2004.22437.x
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Table 1
Keratin Main expression pattern Helix initiation motif Helix termination motif Other regions
K6a As for K16, below PC-1 PC-1 ?
K16 Nail bed, palmoplantar epidermis
(widespread), oral mucosa, wound healing
PC-1, FNEPPK FNEPPK PC-1 tarda
K6b As for K17, below ? PC-2 ?
K17 Nail bed, palmoplantar epidermis (restricted),
epidermal appendages, sebaceous gland, other epithelia
PC-2, SM ? PC-2 tarda
Figure 2
Schematic diagram showing the basic protein structure of a type I
keratin. The a-helical rod domain is divided into four domains, the 1A,
1B, 2A and 2B connected by flexible linkers L1, L12 and L2. Non-helical
variable domains V1 and V2 flank the rod domain. At either end of the
rod domain are the highly conserved helix initiation and helix
termination motifs, respectively (shaded). The approximate positions
of mutations reported in late-onset PC are shown by arrows.
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